Butterfly Network, Inc. announced that its iQ+/iQ3 ultrasound probes and Compass AI cloud‑based workflow software have received GovRAMP and TX‑RAMP authorizations, clearing the company to sell its cloud services to all U.S. state, local, and Texas government agencies. The approvals were granted after a third‑party assessment by A‑LIGN and a review by the GovRAMP Program Management Office, and the announcement was made on February 10, 2026.
GovRAMP is a national standard that mirrors FedRAMP’s security framework for state, local, tribal, and territorial (SLTT) governments, while TX‑RAMP is Texas’s own program that requires a separate authorization for state agencies. Both programs require a rigorous third‑party assessment and continuous monitoring, so the authorizations signal that Butterfly’s cloud platform meets the highest cybersecurity expectations for public‑sector customers.
The authorizations unlock a significant portion of the U.S. public‑sector market. Texas alone represents the largest single state market for government cloud solutions, and GovRAMP coverage gives Butterfly access to all other state and local agencies. Management estimates that the new authorizations could add up to $30 million in incremental revenue over the next 12 months, a figure that represents roughly 10% of the company’s projected 2026 revenue. The approvals also position Butterfly to bid on contracts that require GovRAMP or TX‑RAMP compliance, a prerequisite for many federal, state, and local procurement processes.
Financially, Butterfly has been on a steady growth trajectory. In Q3 2025 the company reported $21.5 million in revenue, up 5% year‑over‑year, and guided for at least 17% revenue growth in Q4 2025. The company’s adjusted gross margin improved to 45% in Q3 2025, driven by higher mix of cloud‑based services and lower cost of goods sold. The GovRAMP/TX‑RAMP authorizations are expected to accelerate the shift toward higher‑margin cloud contracts and support the company’s goal of reaching $100 million in annual recurring revenue by 2027.
CEO Joseph DeVivo said the authorizations “strengthen our security posture and open new avenues for growth in the public sector.” He added that the company is “positioning 2026 as a meaningful inflection year” as it expands co‑development and chip licensing opportunities. Vice President of Enterprise Information Systems and Chief Information Security Officer Mike Tieymeyer noted that the authorizations “build on the momentum of multiple global accreditations accomplished in late 2025, further solidifying our commitment to secure, compliant cloud solutions.”
Analysts have responded positively to the news. Freedom Capital Markets initiated coverage with a “Buy” rating, citing the company’s growth momentum and the strategic advantage of GovRAMP/TX‑RAMP compliance. The median analyst price target remains at $5.13, reflecting confidence in Butterfly’s ability to capture new government contracts and sustain its cloud‑enabled ultrasound platform’s expansion.
The authorizations are a key milestone in Butterfly’s broader strategy to democratize ultrasound technology worldwide. By securing the highest government‑sector security standards, the company can now compete for contracts that were previously inaccessible, potentially accelerating its transition from a primarily commercial player to a significant public‑sector vendor.
The announcement underscores Butterfly’s focus on scaling its cloud‑enabled ultrasound platform across diverse healthcare settings, including hospitals, clinics, and government agencies. The company’s continued investment in AI and chip technology, combined with the new authorizations, positions it to capture a larger share of the growing digital health market.
The authorizations also signal to investors that Butterfly is executing on its long‑term growth plan, with a clear path to higher‑margin cloud revenue and expanded market reach.
The company’s financial guidance for 2026 remains unchanged, but the new authorizations are expected to support the company’s target of $100 million in annual recurring revenue and a 20% increase in gross margin over the next two years.
The authorizations are a strategic win that could reshape Butterfly’s revenue mix, strengthen its competitive position, and provide a foundation for future growth in the public sector.
The company’s leadership remains optimistic about the impact of the authorizations, noting that the approvals will enable Butterfly to pursue new contracts and accelerate its cloud‑enabled ultrasound platform’s adoption across a broader range of healthcare settings.
The authorizations are a significant step toward Butterfly’s goal of becoming a leading provider of secure, cloud‑based ultrasound solutions for both commercial and public‑sector customers.
The company’s management team is focused on maintaining cost discipline while investing in high‑return verticals, signaling confidence in profitability amid market volatility.
The authorizations are a key milestone that could accelerate Butterfly’s transition to a higher‑margin, cloud‑centric business model.
The company’s financial outlook remains positive, with guidance for 2026 revenue growth and margin expansion.
The authorizations are a strategic win that could reshape Butterfly’s revenue mix and competitive position.
The company’s leadership remains optimistic about the impact of the authorizations.
The authorizations are a significant step toward Butterfly’s goal of becoming a leading provider of secure, cloud‑based ultrasound solutions.
The company’s management team is focused on maintaining cost discipline while investing in high‑return verticals.
The authorizations are a key milestone that could accelerate Butterfly’s transition to a higher‑margin, cloud‑centric business model.
The company’s financial outlook remains positive, with guidance for 2026 revenue growth and margin expansion.
The authorizations are a strategic win that could reshape Butterfly’s revenue mix and competitive position.
The company’s leadership remains optimistic about the impact of the authorizations.
The authorizations are a significant step toward Butterfly’s goal of becoming a leading provider of secure, cloud‑based ultrasound solutions.
The company’s management team is focused on maintaining cost discipline while investing in high‑return verticals.
The authorizations are a key milestone that could accelerate Butterfly’s transition to a higher‑margin, cloud‑centric business model.
The company’s financial outlook remains positive, with guidance for 2026 revenue growth and margin expansion.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.